Clinical Trials for Non-Small Cell Lung Cancer

A Randomized, Phase 3, Open-label Study to Evaluate Sigvotatug Vedotin Compared With Docetaxel in Adult Participants With Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

HealthScout AI summary: This trial compares sigvotatug vedotin, an antibody-drug conjugate targeting integrin beta-6, against docetaxel in previously treated adult patients with locally advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior platinum-based chemotherapy and anti-PD-(L)1 agents.

ClinicalTrials.gov ID: NCT06012435

A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (HARMONi-3)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

HealthScout AI summary: This trial involves adult patients with metastatic squamous non-small cell lung cancer who have not previously received systemic treatment, comparing the efficacy and safety of ivonescimab, a novel antibody potentially targeting multiple pathways, combined with chemotherapy, against pembrolizumab, a PD-1 inhibitor, combined with chemotherapy.

ClinicalTrials.gov ID: NCT05899608

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

HealthScout AI summary: This trial evaluates divarasib, a novel oral KRAS G12C inhibitor, against sotorasib and adagrasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have progressed after 1-3 prior treatments, aiming to assess efficacy and safety among these therapies.

ClinicalTrials.gov ID: NCT06497556

A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

HealthScout AI summary: This trial compares DZD9008, an investigational EGFR tyrosine kinase inhibitor targeting exon 20 insertion mutations, to standard platinum-based chemotherapy in treatment-naïve adult patients with locally advanced or metastatic non-squamous NSCLC harboring EGFR exon 20 insertion mutations.

ClinicalTrials.gov ID: NCT05668988

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50%

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets participants with metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression of ≥50%, comparing overall survival with the combination of sacituzumab tirumotecan, a TROP2-targeting antibody-drug conjugate, and pembrolizumab, to pembrolizumab alone.

ClinicalTrials.gov ID: NCT06170788

Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients aged 18 or older with locally advanced or metastatic nonsquamous NSCLC harboring EGFR exon 20 insertion mutations, evaluating the efficacy and safety of the investigational drug zipalertinib, an oral tyrosine kinase inhibitor targeting these mutations, in combination with standard chemotherapy versus chemotherapy alone.

ClinicalTrials.gov ID: NCT05973773

Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets adult patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations, comparing the investigational drug zongertinib, a HER2-targeted tyrosine kinase inhibitor, against the standard treatment of pembrolizumab combined with platinum-pemetrexed chemotherapy as first-line therapy.

ClinicalTrials.gov ID: NCT06151574

A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This study involves adult patients with advanced or metastatic NSCLC without EGFR, ALK, or ROS1 mutations that have progressed after front-line ICI-based maintenance therapy, comparing the safety and efficacy of the oncolytic vaccinia virus Olvi-Vec with platinum-doublet chemotherapy and a chosen ICI versus docetaxel.

ClinicalTrials.gov ID: NCT06463665

A Phase 2 Study of Defactinib and Avutometinib, in Combination With Nivolumab for Patients With Anti-PD1 Refractory LKB1-Mutant Advanced Lung Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients with advanced LKB1-mutant non-small cell lung cancer refractory to prior anti-PD1 treatment, including a cohort with KRAS mutations, who will receive a combination of defactinib (a focal adhesion kinase inhibitor), avutometinib (a dual RAF/MEK inhibitor), and nivolumab (a PD-1 blocking antibody).

ClinicalTrials.gov ID: NCT06495125

A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1 TPS ≥50%

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients with stage IV KRAS G12C-mutant metastatic NSCLC and PD-L1 TPS ≥50%, comparing the combination of MK-1084, a selective KRAS G12C-GDP inhibitor, with pembrolizumab against pembrolizumab plus a placebo as first-line treatment.

ClinicalTrials.gov ID: NCT06345729